|

Liver Cancer Clinical Trials in Philadelphia, PA

33 recruiting studies within 50 miles

Phase
Trial Phase Dist.
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT—<1 mi
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaPhase 3<1 mi
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry—<1 mi
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid TumorsPhase 1<1 mi
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or LymphomaPhase 3<1 mi
National Liver Cancer Screening TrialPhase 4<1 mi
SBRT With Atezo/Bev for HCCPhase 1<1 mi
Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients—<1 mi
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)N/A<1 mi
Dose-defining Study of Tirapazamine Combined With Embolization in Liver CancerPhase 1/2<1 mi
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine TumorsPhase 2<1 mi
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)Phase 1<1 mi
Tebentafusp-tebn With LDT in Metastatic UMPhase 1/2<1 mi
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid TumorsPhase 1/2<1 mi
Y-90 Treatment Response Using Transarterial RadioembolizationPhase 2<1 mi
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer—<1 mi
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 CirrhosisPhase 2<1 mi
Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver TumorsPhase 2<1 mi
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRIN/A<1 mi
DESTINY-PANTUMOUR04—<1 mi
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 YearsPhase 4<1 mi
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery—<1 mi
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and ChemotherapyPhase 3<1 mi
A Study of Novel Study Interventions and Combinations in Participants With Colorectal CancerPhase 2<1 mi
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP TrialPhase 3<1 mi
Observational Study Protocol: LIVER-R—<1 mi
CapTemY90 for Grade 2/3 NET Liver MetastasesPhase 2<1 mi
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine RegimenPhase 3<1 mi
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCCPhase 2<1 mi
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsPhase 1/2<1 mi
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver ImpairmentPhase 136 mi
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)—48 mi
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)Phase 248 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.